{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:06:20Z","timestamp":1794956780979,"version":"4.9.1"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302970"],"award-info":[{"award-number":["82302970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["ZYN2024205"],"award-info":[{"award-number":["ZYN2024205"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic regulation is a fundamental mechanism controlling gene expression and cellular function, primarily mediated through reversible modifications such as DNA methylation, histone acetylation, and chromatin remodeling. Dysregulation of critical epigenetic enzymes, including histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and bromodomain and extraterminal domain (BET) proteins, has been closely associated with tumor initiation, progression, metastasis, immune evasion, and resistance to conventional therapies. Targeting these epigenetic regulators with small-molecule inhibitors or degraders has emerged as a promising therapeutic strategy, capable of reprogramming aberrant transcriptional networks and reshaping the tumor microenvironment. Beyond direct cytotoxic effects, epigenetic drugs have demonstrated the ability to enhance antitumor immunity by restoring antigen presentation, promoting immunogenic cell death, modulating cytokine profiles, and reversing local immune suppression. Recent preclinical and clinical studies have highlighted the potential of combining epigenetic therapies with immune checkpoint inhibitors to achieve synergistic antitumor responses and overcome resistance mechanisms. This review provides a comprehensive summary of the mechanisms of action, pharmacological characteristics, and clinical applications of epigenetic drugs, with a focus on innovative combination strategies and ongoing translational advancements. We also discuss future directions, emphasizing the need to improve drug specificity, minimize off-target effects, integrate personalized immunotherapeutic approaches, and identify predictive biomarkers to optimize patient selection and clinical outcomes. Overall, epigenetic therapy represents a versatile and evolving avenue for precision oncology with broad implications for tumor control and immunomodulation.<\/jats:p>","DOI":"10.1186\/s43556-025-00373-5","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:05:08Z","timestamp":1764752708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications"],"prefix":"10.1186","volume":"6","author":[{"given":"Chen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1389-0546","authenticated-orcid":false,"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"6","key":"373_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-025-01143-0","volume":"22","author":"L Chiapperino","year":"2025","unstructured":"Chiapperino L, Habets M, Paneni F. Epigenetic editing in cardiovascular medicine: moving beyond the hype. Nat Rev Cardiol. 2025;22(6):389\u201390. https:\/\/doi.org\/10.1038\/s41569-025-01143-0.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"373_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683\u201392. https:\/\/doi.org\/10.1016\/j.cell.2007.01.029.","journal-title":"Cell"},{"issue":"4","key":"373_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrg2005","volume":"8","author":"M Esteller","year":"2007","unstructured":"Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286\u201398. https:\/\/doi.org\/10.1038\/nrg2005.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"373_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, My\u00f6h\u00e4nen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103\u20137. https:\/\/doi.org\/10.1038\/5047.","journal-title":"Nat Genet"},{"issue":"7","key":"373_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650\u201363. https:\/\/doi.org\/10.1056\/NEJMra1805035.","journal-title":"N Engl J Med"},{"issue":"1","key":"373_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85\u201393. https:\/\/doi.org\/10.1016\/0092-8674(80)90237-8.","journal-title":"Cell"},{"issue":"6990","key":"373_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457\u201363. https:\/\/doi.org\/10.1038\/nature02625.","journal-title":"Nature"},{"issue":"1","key":"373_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22(1):91. https:\/\/doi.org\/10.1186\/s12943-023-01782-2.","journal-title":"Mol Cancer"},{"issue":"8","key":"373_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629\u201351. https:\/\/doi.org\/10.1038\/s41573-021-00219-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"6632","key":"373_CR10","doi-asserted-by":"publisher","first-page":"eaaw3835","DOI":"10.1126\/science.aaw3835","volume":"379","author":"AP Feinberg","year":"2023","unstructured":"Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379(6632):eaaw3835. https:\/\/doi.org\/10.1126\/science.aaw3835.","journal-title":"Science"},{"issue":"8","key":"373_CR11","doi-asserted-by":"publisher","first-page":"e2006134","DOI":"10.1371\/journal.pbio.2006134","volume":"16","author":"L Wu","year":"2018","unstructured":"Wu L, Cao J, Cai WL, Lang SM, Horton JR, Jansen DJ, et al. KDM5 histone demethylases repress immune response via suppression of STING. PLoS Biol. 2018;16(8):e2006134. https:\/\/doi.org\/10.1371\/journal.pbio.2006134.","journal-title":"PLoS Biol"},{"issue":"6626","key":"373_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.abn4009","volume":"378","author":"SE Johnstone","year":"2022","unstructured":"Johnstone SE, Gladyshev VN, Aryee MJ, Bernstein BE. Epigenetic clocks, aging, and cancer. Science. 2022;378(6626):1276\u20137. https:\/\/doi.org\/10.1126\/science.abn4009.","journal-title":"Science"},{"issue":"7827","key":"373_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41586-020-2747-1","volume":"586","author":"TH Xu","year":"2020","unstructured":"Xu TH, Liu M, Zhou XE, Liang G, Zhao G, Xu HE, et al. Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B. Nature. 2020;586(7827):151\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2747-1.","journal-title":"Nature"},{"issue":"8","key":"373_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41556-021-00722-w","volume":"23","author":"W Soochit","year":"2021","unstructured":"Soochit W, Sleutels F, Stik G, Bartkuhn M, Basu S, Hernandez SC, et al. CTCF chromatin residence time controls three-dimensional genome organization, gene expression and DNA methylation in pluripotent cells. Nat Cell Biol. 2021;23(8):881\u201393. https:\/\/doi.org\/10.1038\/s41556-021-00722-w.","journal-title":"Nat Cell Biol"},{"issue":"24","key":"373_CR15","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","volume":"119","author":"AF Ribeiro","year":"2012","unstructured":"Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119(24):5824\u201331. https:\/\/doi.org\/10.1182\/blood-2011-07-367961.","journal-title":"Blood"},{"issue":"2","key":"373_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81\u201392. https:\/\/doi.org\/10.1038\/nrg.2017.80.","journal-title":"Nat Rev Genet"},{"issue":"6632","key":"373_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1126\/science.aaw3835","volume":"379","author":"AP Feinberg","year":"2023","unstructured":"Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379(6632):552. https:\/\/doi.org\/10.1126\/science.aaw3835.","journal-title":"Science"},{"issue":"8","key":"373_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics \u2014 challenges and potential solutions. Nat Rev Drug Discovery. 2021;20(8):629\u201351. https:\/\/doi.org\/10.1038\/s41573-021-00219-z.","journal-title":"Nat Rev Drug Discovery"},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1476-4598-9-305","volume":"9","author":"GL Gravina","year":"2010","unstructured":"Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305. https:\/\/doi.org\/10.1186\/1476-4598-9-305.","journal-title":"Mol Cancer"},{"issue":"5","key":"373_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/cam4.4535","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cheng H, Cheng C, Zheng F, Zhao Z, Chen Q, et al. ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. Cancer Med. 2022;11(5):1269\u201380. https:\/\/doi.org\/10.1002\/cam4.4535.","journal-title":"Cancer Med"},{"issue":"11","key":"373_CR21","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1182\/blood.V108.11.4303.4303","volume":"108","author":"SH Choi","year":"2006","unstructured":"Choi SH, Byun H-M, Kwan J, Yang AS. Hydroxyurea with azacitidine or decitabine in combination is antagonistic on DNA methylation inhibition. Blood. 2006;108(11):4303. https:\/\/doi.org\/10.1182\/blood.V108.11.4303.4303.","journal-title":"Blood"},{"issue":"10","key":"373_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/s1470-2045(17)30576-4","volume":"18","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O\u2019Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial. LANCET ONCOLOGY. 2017;18(10):1317\u201326. https:\/\/doi.org\/10.1016\/s1470-2045(17)30576-4.","journal-title":"LANCET ONCOLOGY"},{"issue":"1","key":"373_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1479-5876-8-92","volume":"8","author":"D Lavelle","year":"2010","unstructured":"Lavelle D, Saunthararajah Y, Vaitkus K, Singh M, Banzon V, Phiasivongsva P, et al. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med. 2010;8(1):92. https:\/\/doi.org\/10.1186\/1479-5876-8-92.","journal-title":"J Transl Med"},{"issue":"7","key":"373_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","volume":"98","author":"SD Gore","year":"2013","unstructured":"Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98(7):1067\u201372. https:\/\/doi.org\/10.3324\/haematol.2012.074831.","journal-title":"Haematologica"},{"issue":"3","key":"373_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(09)70003-8.","journal-title":"Lancet Oncol"},{"key":"373_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2407-14-69","volume":"14","author":"J Mayer","year":"2014","unstructured":"Mayer J, Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, et al. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. BMC Cancer. 2014;14:69. https:\/\/doi.org\/10.1186\/1471-2407-14-69.","journal-title":"BMC Cancer"},{"issue":"21","key":"373_CR27","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/jco.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u20137. https:\/\/doi.org\/10.1200\/jco.2011.38.9429.","journal-title":"J Clin Oncol"},{"issue":"8","key":"373_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/cac2.12326","volume":"42","author":"Z Sun","year":"2022","unstructured":"Sun Z, Wang X, Vedell P, Kocher J-P. DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines. Cancer Commun. 2022;42(8):789\u201392. https:\/\/doi.org\/10.1002\/cac2.12326.","journal-title":"Cancer Commun"},{"issue":"10","key":"373_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002\u201317. https:\/\/doi.org\/10.1038\/s43018-021-00249-x.","journal-title":"Nat Cancer"},{"issue":"1","key":"373_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.59","volume":"3","author":"L Tao","year":"2024","unstructured":"Tao L, Zhou Y, Luo Y, Qiu J, Xiao Y, Zou J, et al. Epigenetic regulation in cancer therapy: from mechanisms to clinical advances. MedComm \u2013 Oncology. 2024;3(1):e59. https:\/\/doi.org\/10.1002\/mog2.59.","journal-title":"MedComm \u2013 Oncology"},{"key":"373_CR31","doi-asserted-by":"publisher","first-page":"2543504","DOI":"10.1155\/2020\/2543504","volume":"2020","author":"R Tong","year":"2020","unstructured":"Tong R, Wu X, Liu Y, Liu Y, Zhou J, Jiang X, et al. Curcumin-induced DNA demethylation in human gastric cancer cells is mediated by the DNA-damage response pathway. Oxid Med Cell Longev. 2020;2020:2543504. https:\/\/doi.org\/10.1155\/2020\/2543504.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"373_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3892\/or.2020.7473","volume":"43","author":"N Al-Yousef","year":"2020","unstructured":"Al-Yousef N, Shinwari Z, Al-Shahrani B, Al-Showimi M, Al-Moghrabi N. Curcumin induces re-expression of BRCA1 and suppression of \u03b3 synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncol Rep. 2020;43(3):827\u201338. https:\/\/doi.org\/10.3892\/or.2020.7473.","journal-title":"Oncol Rep"},{"issue":"20","key":"373_CR33","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.Ccr-04-0744","volume":"10","author":"RA Sharma","year":"2004","unstructured":"Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847\u201354. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0744.","journal-title":"Clin Cancer Res"},{"key":"373_CR34","doi-asserted-by":"publisher","first-page":"705903","DOI":"10.3389\/fonc.2021.705903","volume":"11","author":"W Jiang","year":"2021","unstructured":"Jiang W, Xia T, Liu C, Li J, Zhang W, Sun C. Remodeling the epigenetic landscape of cancer-application potential of flavonoids in the prevention and treatment of cancer. Front Oncol. 2021;11:705903. https:\/\/doi.org\/10.3389\/fonc.2021.705903.","journal-title":"Front Oncol"},{"issue":"4","key":"373_CR35","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3892\/or.2015.3802","volume":"33","author":"MA Khan","year":"2015","unstructured":"Khan MA, Hussain A, Sundaram MK, Alalami U, Gunasekera D, Ramesh L, et al. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol Rep. 2015;33(4):1976\u201384. https:\/\/doi.org\/10.3892\/or.2015.3802.","journal-title":"Oncol Rep"},{"issue":"1","key":"373_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13148-018-0563-3","volume":"10","author":"MC Alvarez","year":"2018","unstructured":"Alvarez MC, Maso V, Torello CO, Ferro KP, Saad STO. The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. Clin Epigenetics. 2018;10(1):139. https:\/\/doi.org\/10.1186\/s13148-018-0563-3.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"373_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11095-024-03810-2","volume":"42","author":"HH Hsieh","year":"2025","unstructured":"Hsieh HH, Kuo MZ, Chen IA, Lin CJ, Hsu V, HuangFu WC, et al. Epigenetic modifications as novel therapeutic strategies of cancer chemoprevention by phytochemicals. Pharm Res. 2025;42(1):69\u201378. https:\/\/doi.org\/10.1007\/s11095-024-03810-2.","journal-title":"Pharm Res"},{"issue":"10","key":"373_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s43018-021-00271-z","volume":"2","author":"P Mehdipour","year":"2021","unstructured":"Mehdipour P, Chen R, De Carvalho DD. The next generation of DNMT inhibitors. Nat Cancer. 2021;2(10):1000\u20131. https:\/\/doi.org\/10.1038\/s43018-021-00271-z.","journal-title":"Nat Cancer"},{"issue":"3","key":"373_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10555-010-9235-2","volume":"29","author":"SC Gupta","year":"2010","unstructured":"Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010;29(3):405\u201334. https:\/\/doi.org\/10.1007\/s10555-010-9235-2.","journal-title":"Cancer Metastasis Rev"},{"key":"373_CR40","doi-asserted-by":"publisher","first-page":"103446","DOI":"10.1016\/j.fbio.2023.103446","volume":"57","author":"SM Amini","year":"2024","unstructured":"Amini SM, Emami T, Rashidi M, Zrrinnahad H. Curcumin-gold nanoformulation: Synthesis, characterizations and biomedical application. Food Biosci. 2024;57:103446. https:\/\/doi.org\/10.1016\/j.fbio.2023.103446.","journal-title":"Food Biosci"},{"issue":"5","key":"373_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1208\/s12249-025-03145-0","volume":"26","author":"M Qutub","year":"2025","unstructured":"Qutub M, Hussain UM, Tatode A, Premchandani T, Khan R, Umekar M, et al. Nano-engineered epigallocatechin gallate (EGCG) delivery systems: overcoming bioavailability barriers to unlock clinical potential in cancer therapy. AAPS PharmSciTech. 2025;26(5):137. https:\/\/doi.org\/10.1208\/s12249-025-03145-0.","journal-title":"AAPS PharmSciTech"},{"issue":"57","key":"373_CR42","doi-asserted-by":"publisher","first-page":"34517","DOI":"10.1039\/d0ra04231e","volume":"10","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M, et al. Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA. RSC Adv. 2020;10(57):34517\u201326. https:\/\/doi.org\/10.1039\/d0ra04231e.","journal-title":"RSC Adv"},{"issue":"1","key":"373_CR43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12951-025-03546-0","volume":"23","author":"G Chen","year":"2025","unstructured":"Chen G, Song W, Wang X, Mao G, Hu W, Dou R, et al. Quercetin combined with shTERT induces apoptosis in ovarian cancer via the P53\/Bax pathway, and RGD-MSN\/QR\/shTERT nanoparticles enhance the therapeutic efficacy. J Nanobiotechnology. 2025;23(1):536. https:\/\/doi.org\/10.1186\/s12951-025-03546-0.","journal-title":"J Nanobiotechnology"},{"issue":"10","key":"373_CR44","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41590-024-01947-1","volume":"25","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Lieberman J. Emerging tumor repression of immune recognition is reversed by inhibiting DNA methylation. Nat Immunol. 2024;25(10):1787\u20138. https:\/\/doi.org\/10.1038\/s41590-024-01947-1.","journal-title":"Nat Immunol"},{"issue":"12","key":"373_CR45","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1093\/nar\/gkad294","volume":"51","author":"S Wang","year":"2023","unstructured":"Wang S, Fairall L, Pham TK, Ragan TJ, Vashi D, Collins MO, et al. A potential histone-chaperoneactivity for the MIER1 histone deacetylase complex. Nucleic Acids Res. 2023;51(12):6006\u201319. https:\/\/doi.org\/10.1093\/nar\/gkad294.","journal-title":"Nucleic Acids Res"},{"key":"373_CR46","doi-asserted-by":"publisher","unstructured":"Hancock WWM, PhD, FRCPA. Isoform-Selective HDAC Inhibitor Therapy for Transplantation. TRANSPLANTATION. 2016;100(8):1597-8. https:\/\/doi.org\/10.1097\/tp.0000000000001209.","DOI":"10.1097\/tp.0000000000001209"},{"key":"373_CR47","doi-asserted-by":"publisher","first-page":"175216","DOI":"10.1016\/j.ejphar.2022.175216","volume":"931","author":"R Hai","year":"2022","unstructured":"Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol. 2022;931:175216. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175216.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"373_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","volume":"39","author":"T Singh","year":"2022","unstructured":"Singh T, Kaur P, Singh P, Singh S, Munshi A. Differential molecular mechanistic behavior of HDACs in cancer progression. Med Oncol. 2022;39(11):171. https:\/\/doi.org\/10.1007\/s12032-022-01770-4.","journal-title":"Med Oncol"},{"key":"373_CR49","doi-asserted-by":"publisher","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"issue":"7","key":"373_CR50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.lfs.2021.119504","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends in cancer. 2020;6(7):580\u201392. https:\/\/doi.org\/10.1016\/j.lfs.2021.119504.","journal-title":"Trends in cancer"},{"issue":"4","key":"373_CR51","first-page":"769","volume":"18","author":"M Nakagawa","year":"2007","unstructured":"Nakagawa M, Oda Y, Eguchi T, Aishima S-I, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007;18(4):769\u201374.","journal-title":"Oncol Rep"},{"issue":"14","key":"373_CR52","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/cancers13143575","volume":"13","author":"D Karagiannis","year":"2021","unstructured":"Karagiannis D, Rampias T. HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity. Cancers. 2021;13(14):3575. https:\/\/doi.org\/10.3390\/cancers13143575.","journal-title":"Cancers"},{"issue":"3","key":"373_CR53","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3892\/or.2013.2578","volume":"30","author":"S-L Yu","year":"2013","unstructured":"Yu S-L, Lee DC, Son JW, Park CG, Lee HY, Kang J. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells. Oncol Rep. 2013;30(3):1293\u2013300. https:\/\/doi.org\/10.3892\/or.2013.2578.","journal-title":"Oncol Rep"},{"issue":"6","key":"373_CR54","first-page":"6434","volume":"8","author":"Q Liu","year":"2015","unstructured":"Liu Q, Sun Y, Zheng J-M, Yan X-L, Chen H-M, Chen J-K, et al. Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5. Int J Clin Exp Pathol. 2015;8(6):6434.","journal-title":"Int J Clin Exp Pathol"},{"issue":"24","key":"373_CR55","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.3390\/cancers13246280","volume":"13","author":"E Passaro","year":"2021","unstructured":"Passaro E, Papulino C, Chianese U, Toraldo A, Congi R, Del Gaudio N, et al. HDAC6 inhibition extinguishes autophagy in cancer: recent insights. Cancers. 2021;13(24):6280. https:\/\/doi.org\/10.3390\/cancers13246280.","journal-title":"Cancers"},{"issue":"5","key":"373_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","volume":"45","author":"S Kaur","year":"2022","unstructured":"Kaur S, Rajoria P, Chopra M. HDAC6: a unique HDAC family member as a cancer target. Cell Oncol. 2022;45(5):779\u2013829. https:\/\/doi.org\/10.1007\/s13402-022-00704-6.","journal-title":"Cell Oncol"},{"issue":"10","key":"373_CR57","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrc3985","volume":"15","author":"A Chalkiadaki","year":"2015","unstructured":"Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015;15(10):608\u201324. https:\/\/doi.org\/10.1038\/nrc3985.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"373_CR58","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/1947601911417862","volume":"2","author":"L Bosch-Presegu\u00e9","year":"2011","unstructured":"Bosch-Presegu\u00e9 L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer. 2011;2(6):648\u201362. https:\/\/doi.org\/10.1177\/1947601911417862.","journal-title":"Genes Cancer"},{"key":"373_CR59","doi-asserted-by":"publisher","first-page":"110607","DOI":"10.1016\/j.biopha.2020.110607","volume":"131","author":"S-S Liu","year":"2020","unstructured":"Liu S-S, Wu F, Jin Y-M, Chang W-Q, Xu T-M. HDAC11: a rising star in epigenetics. Biomed Pharmacother. 2020;131:110607. https:\/\/doi.org\/10.1016\/j.biopha.2020.110607.","journal-title":"Biomed Pharmacother"},{"key":"373_CR60","doi-asserted-by":"publisher","first-page":"989305","DOI":"10.3389\/fendo.2022.989305","volume":"13","author":"H Chen","year":"2022","unstructured":"Chen H, Xie C, Chen Q, Zhuang S. HDAC11, an emerging therapeutic target for metabolic disorders. Front Endocrinol. 2022;13:989305. https:\/\/doi.org\/10.3389\/fendo.2022.989305.","journal-title":"Front Endocrinol"},{"issue":"1","key":"373_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/pharmaceutics14010209","volume":"14","author":"D Ruzic","year":"2022","unstructured":"Ruzic D, Djokovic N, Srdic-Rajic T, Echeverria C, Nikolic K, Santibanez JF. Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention. Pharmaceutics. 2022;14(1):209. https:\/\/doi.org\/10.3390\/pharmaceutics14010209.","journal-title":"Pharmaceutics"},{"key":"373_CR62","doi-asserted-by":"publisher","first-page":"103184","DOI":"10.1016\/j.bioorg.2019.103184","volume":"91","author":"M Huang","year":"2019","unstructured":"Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: promising agents for breast cancer treatment. Bioorg Chem. 2019;91:103184. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103184.","journal-title":"Bioorg Chem"},{"issue":"22","key":"373_CR63","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.3390\/ijms21228828","volume":"21","author":"Y Luo","year":"2020","unstructured":"Luo Y, Li H. Structure-based inhibitor discovery of class I histone deacetylases (HDACs). Int J Mol Sci. 2020;21(22):8828. https:\/\/doi.org\/10.3390\/ijms21228828.","journal-title":"Int J Mol Sci"},{"key":"373_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.fct.2014.08.005","volume":"73","author":"M Miceli","year":"2014","unstructured":"Miceli M, Bontempo P, Nebbioso A, Altucci L. Natural compounds in epigenetics: a current view. Food Chem Toxicol. 2014;73:71\u201383. https:\/\/doi.org\/10.1016\/j.fct.2014.08.005.","journal-title":"Food Chem Toxicol"},{"key":"373_CR65","doi-asserted-by":"publisher","unstructured":"Mrakovcic M, Bohner L, Hanisch M, Fr\u00f6hlich LF. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. Int J Mol Sci. 2018;19(12). https:\/\/doi.org\/10.3390\/ijms19123952.","DOI":"10.3390\/ijms19123952"},{"issue":"20","key":"373_CR66","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1073\/pnas.1205132109","volume":"109","author":"H Lee","year":"2012","unstructured":"Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A. 2012;109(20):7765\u20139. https:\/\/doi.org\/10.1073\/pnas.1205132109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"373_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","volume":"67","author":"M Manal","year":"2016","unstructured":"Manal M, Chandrasekar MJN, Priya JG, Nanjan MJ. Inhibitors of histone deacetylase as antitumor agents: a critical review. Bioorg Chem. 2016;67:18\u201342. https:\/\/doi.org\/10.1016\/j.bioorg.2016.05.005.","journal-title":"Bioorg Chem"},{"key":"373_CR68","doi-asserted-by":"publisher","first-page":"117185","DOI":"10.1016\/j.ejmech.2024.117185","volume":"283","author":"Z Lv","year":"2025","unstructured":"Lv Z, Ji T, Liu J, Sun X, Liang H. Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review. Eur J Med Chem. 2025;283:117185. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117185.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"373_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1568026619666190122144949","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, Wang F, Chen X, Wang J, Zhao Y, Li Y, et al. Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups. Curr Top Med Chem. 2019;19(3):223\u201341. https:\/\/doi.org\/10.2174\/1568026619666190122144949.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"373_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/cancers11040475","volume":"11","author":"Y Imai","year":"2019","unstructured":"Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers. 2019;11(4):475. https:\/\/doi.org\/10.3390\/cancers11040475.","journal-title":"Cancers"},{"issue":"8","key":"373_CR71","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","volume":"64","author":"KM VanderMolen","year":"2011","unstructured":"VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot. 2011;64(8):525\u201331. https:\/\/doi.org\/10.1038\/ja.2011.35.","journal-title":"J Antibiot"},{"issue":"23","key":"373_CR72","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.2782.","journal-title":"J Clin Oncol"},{"issue":"12","key":"373_CR73","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.Ccr-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13(12):3605\u201310. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0162.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"373_CR74","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1021\/cr400135x","volume":"114","author":"C Santini","year":"2014","unstructured":"Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C. Advances in copper complexes as anticancer agents. Chem Rev. 2014;114(1):815\u201362. https:\/\/doi.org\/10.1021\/cr400135x.","journal-title":"Chem Rev"},{"issue":"8","key":"373_CR75","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cbic.201900676","volume":"21","author":"DLJ Stephens","year":"2020","unstructured":"Stephens DLJ, Levina DA, Trinh DI, Blair DVL, Werrett DMV, Lay PPA, et al. Ruthenium(II)\u2013arene thiocarboxylates: identification of a stable dimer selectively cytotoxic to invasive breast cancer cells. ChemBioChem. 2020;21(8):1188\u2013200. https:\/\/doi.org\/10.1002\/cbic.201900676.","journal-title":"ChemBioChem"},{"key":"373_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ejmech.2018.03.015","volume":"150","author":"M Pal","year":"2018","unstructured":"Pal M, Nandi U, Mukherjee D. Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents. Eur J Med Chem. 2018;150:419\u201345. https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.015.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"373_CR77","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/nu10060731","volume":"10","author":"AK Singh","year":"2018","unstructured":"Singh AK, Bishayee A, Pandey AK. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients. 2018;10(6):731.","journal-title":"Nutrients"},{"key":"373_CR78","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11101-020-09684-7","volume":"19","author":"C-Y Li","year":"2020","unstructured":"Li C-Y, Chung Y-M, Wu Y-C, Hunyadi A, Wang CC, Chang F-R. Natural products development under epigenetic modulation in fungi. Phytochem Rev. 2020;19:1323\u201340. https:\/\/doi.org\/10.1007\/s11101-020-09684-7.","journal-title":"Phytochem Rev"},{"key":"373_CR79","doi-asserted-by":"crossref","unstructured":"Puttalingaiah S, Greeshma MV, Kuruburu MG, Bovilla VR, Madhunapantula SV. Naturally Occurring Histone Deacetylase (HDAC) Inhibitors in the Treatment of Cancers. Medicinal Plants for Cosmetics, Health and Diseases. CRC Press; 2022. p. 123\u201353.","DOI":"10.1201\/9781003108375-8"},{"issue":"4","key":"373_CR80","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1039\/c2np00066k","volume":"29","author":"J Hong","year":"2012","unstructured":"Hong J, Luesch H. Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep. 2012;29(4):449\u201356. https:\/\/doi.org\/10.1039\/c2np00066k.","journal-title":"Nat Prod Rep"},{"issue":"16","key":"373_CR81","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1016\/j.bmcl.2014.07.006","volume":"24","author":"B Kim","year":"2014","unstructured":"Kim B, Park H, Salvador LA, Serrano PE, Kwan JC, Zeller SL, et al. Evaluation of class I HDAC isoform selectivity of largazole analogues. Bioorg Med Chem Lett. 2014;24(16):3728\u201331. https:\/\/doi.org\/10.1016\/j.bmcl.2014.07.006.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"373_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1124\/jpet.110.172387","volume":"335","author":"Y Liu","year":"2010","unstructured":"Liu Y, Salvador LA, Byeon S, Ying Y, Kwan JC, Law BK, et al. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther. 2010;335(2):351\u201361. https:\/\/doi.org\/10.1124\/jpet.110.172387.","journal-title":"J Pharmacol Exp Ther"},{"key":"373_CR83","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00280-015-2675-1","volume":"75","author":"JL Pilon","year":"2015","unstructured":"Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, et al. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol. 2015;75:671\u201382. https:\/\/doi.org\/10.1007\/s00280-015-2675-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"373_CR84","doi-asserted-by":"publisher","first-page":"116510","DOI":"10.1016\/j.bmc.2021.116510","volume":"52","author":"X Qiu","year":"2021","unstructured":"Qiu X, Zhu L, Wang H, Tan Y, Yang Z, Yang L, et al. From natural products to HDAC inhibitors: an overview of drug discovery and design strategy. Bioorg Med Chem. 2021;52:116510. https:\/\/doi.org\/10.1016\/j.bmc.2021.116510.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"373_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13659-025-00511-0","volume":"15","author":"P Quintero-Rinc\u00f3n","year":"2025","unstructured":"Quintero-Rinc\u00f3n P, Caballero-Gallardo K, Olivero-Verbel J. Natural anticancer agents: prospection of medicinal and aromatic plants in modern chemoprevention and chemotherapy. Nat Prod Bioprospect. 2025;15(1):25. https:\/\/doi.org\/10.1007\/s13659-025-00511-0.","journal-title":"Nat Prod Bioprospect"},{"key":"373_CR86","doi-asserted-by":"publisher","first-page":"772915","DOI":"10.3389\/fonc.2021.772915","volume":"11","author":"R Li","year":"2021","unstructured":"Li R, Song X, Guo Y, Song P, Duan D, Chen Z-S. Natural products: a promising therapeutics for targeting tumor angiogenesis. Front Oncol. 2021;11:772915. https:\/\/doi.org\/10.3389\/fonc.2021.772915.","journal-title":"Front Oncol"},{"issue":"7","key":"373_CR87","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1007\/s00210-025-03876-8","volume":"398","author":"BK Utpal","year":"2025","unstructured":"Utpal BK, Bouenni H, Zehravi M, Sweilam SH, Mortuza MR, Arjun UVNV, et al. Exploring natural products as apoptosis modulators in cancers: insights into natural product-based therapeutic strategies. Naunyn-Schmiedebergs Arch Pharmacol. 2025;398(7):8189\u2013214. https:\/\/doi.org\/10.1007\/s00210-025-03876-8.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"15","key":"373_CR88","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.3390\/ijms23158141","volume":"23","author":"RK Alseksek","year":"2022","unstructured":"Alseksek RK, Ramadan WS, Saleh E, El-Awady R. The role of HDACs in the response of cancer cells to cellular stress and the potential for therapeutic intervention. Int J Mol Sci. 2022;23(15):8141. https:\/\/doi.org\/10.3390\/ijms23158141.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"373_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2022","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M, Regiec A. FDA-approved drugs for hematological malignancies\u2014the last decade review. Cancers. 2022;14(1):87. https:\/\/doi.org\/10.3390\/cancers14010087.","journal-title":"Cancers"},{"issue":"23","key":"373_CR90","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139. https:\/\/doi.org\/10.1200\/jco.2014.59.2782.","journal-title":"J Clin Oncol"},{"issue":"8","key":"373_CR91","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","volume":"64","author":"KM VanderMolen","year":"2011","unstructured":"VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64(8):525\u201331. https:\/\/doi.org\/10.1038\/ja.2011.35. (Oberlies NH).","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"373_CR92","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/cancers11040475","volume":"11","author":"Y Imai","year":"2019","unstructured":"Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019;11(4):475. https:\/\/doi.org\/10.3390\/cancers11040475.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"373_CR93","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11101-020-09684-7","volume":"19","author":"C-Y Li","year":"2020","unstructured":"Li C-Y, Chung Y-M, Wu Y-C, Hunyadi A, Wang CCC, Chang F-R. Natural products development under epigenetic modulation in fungi. Phytochem Rev. 2020;19(6):1323\u201340. https:\/\/doi.org\/10.1007\/s11101-020-09684-7.","journal-title":"Phytochem Rev"},{"key":"373_CR94","doi-asserted-by":"publisher","unstructured":"Singh AK, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Nutrients. 2018;10(6). https:\/\/doi.org\/10.3390\/nu10060731.","DOI":"10.3390\/nu10060731"},{"issue":"8","key":"373_CR95","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cbic.201900676","volume":"21","author":"LJ Stephens","year":"2020","unstructured":"Stephens LJ, Levina A, Trinh I, Blair VL, Werrett MV, Lay PA, et al. Ruthenium(II)-arene thiocarboxylates: identification of a stable dimer selectively cytotoxic to invasive breast cancer cells. ChemBioChem. 2020;21(8):1188\u2013200. https:\/\/doi.org\/10.1002\/cbic.201900676.","journal-title":"ChemBioChem"},{"issue":"4","key":"373_CR96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00280-015-2675-1","volume":"75","author":"JL Pilon","year":"2015","unstructured":"Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, et al. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol. 2015;75(4):671\u201382. https:\/\/doi.org\/10.1007\/s00280-015-2675-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"373_CR97","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1002\/mco2.292","volume":"4","author":"R Liu","year":"2023","unstructured":"Liu R, Wu J, Guo H, Yao W, Li S, Lu Y, et al. Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets. MedComm. 2023;4(3):e292. https:\/\/doi.org\/10.1002\/mco2.292.","journal-title":"MedComm"},{"key":"373_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-3701-4-45","volume":"4","author":"E Baxter","year":"2014","unstructured":"Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci. 2014;4:1\u201311. https:\/\/doi.org\/10.1186\/2045-3701-4-45.","journal-title":"Cell Biosci"},{"issue":"6","key":"373_CR99","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/ijc.34559","volume":"153","author":"N Dalpatraj","year":"2023","unstructured":"Dalpatraj N, Naik A, Thakur N. GSK-J4: an H3K27 histone demethylase inhibitor, as a potential anti-cancer agent. Int J Cancer. 2023;153(6):1130\u20138. https:\/\/doi.org\/10.1002\/ijc.34559.","journal-title":"Int J Cancer"},{"issue":"3","key":"373_CR100","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/cr.2012.136","volume":"23","author":"S Chen","year":"2013","unstructured":"Chen S, Shi Y. A new horizon for epigenetic medicine? Cell Res. 2013;23(3):326\u20138. https:\/\/doi.org\/10.1038\/cr.2012.136.","journal-title":"Cell Res"},{"issue":"8","key":"373_CR101","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/cancers10080268","volume":"10","author":"L Pirola","year":"2018","unstructured":"Pirola L, Ciesielski O, Balcerczyk A. The methylation status of the epigenome: its emerging role in the regulation of tumor angiogenesis and tumor growth, and potential for drug targeting. Cancers. 2018;10(8):268. https:\/\/doi.org\/10.3390\/cancers10080268.","journal-title":"Cancers"},{"key":"373_CR102","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejmech.2018.10.040","volume":"161","author":"Y-C Zheng","year":"2019","unstructured":"Zheng YC, Chang J, Wang LC, Ren HM, Pang JR, Liu HM. Lysine demethylase 5B (KDM5B): a potential anti-cancer drug target. Eur J Med Chem. 2019;161:131\u201340.\u00a0https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.040.","journal-title":"Eur J Med Chem"},{"issue":"22","key":"373_CR103","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","volume":"17","author":"X Liu","year":"2011","unstructured":"Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, et al. A novel kinase inhibitor, INCB28060, blocks c-MET\u2013dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1157.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"373_CR104","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/cancers11121821","volume":"11","author":"P Karakaidos","year":"2019","unstructured":"Karakaidos P, Verigos J, Magklara A. LSD1\/KDM1A, a gate-keeper of cancer stemness and a promising therapeutic target. Cancers. 2019;11(12):1821. https:\/\/doi.org\/10.3390\/cancers11121821.","journal-title":"Cancers"},{"key":"373_CR105","doi-asserted-by":"publisher","unstructured":"Cai W, Xiao C, Fan T, Deng Z, Wang D, Liu Y et al. Targeting LSD1 in cancer: Molecular elucidation and recent advances. Cancer Letters. 2024:217093. https:\/\/doi.org\/10.1016\/j.canlet.2024.217093.","DOI":"10.1016\/j.canlet.2024.217093"},{"key":"373_CR106","doi-asserted-by":"publisher","first-page":"1120911","DOI":"10.3389\/fphar.2023.1120911","volume":"14","author":"B Noce","year":"2023","unstructured":"Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911. https:\/\/doi.org\/10.3389\/fphar.2023.1120911.","journal-title":"Front Pharmacol"},{"key":"373_CR107","doi-asserted-by":"publisher","first-page":"114564","DOI":"10.1016\/j.ejmech.2022.114564","volume":"240","author":"J Dong","year":"2022","unstructured":"Dong J, Pervaiz W, Tayyab B, Li D, Kang L, Zhang H, et al. A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors. Eur J Med Chem. 2022;240:114564. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114564.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"373_CR108","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018;174(3):549-63.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.05.052.","journal-title":"Cell"},{"issue":"7","key":"373_CR109","doi-asserted-by":"publisher","first-page":"e0235705","DOI":"10.1371\/journal.pone.0235705","volume":"15","author":"R Soldi","year":"2020","unstructured":"Soldi R, Halder TG, Weston A, Thode T, Drenner K, Lewis R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch\/Sucrose-NonFermentable (SWI\/SNF) complex mutated ovarian cancer. PLoS ONE. 2020;15(7):e0235705. https:\/\/doi.org\/10.1371\/journal.pone.0235705.","journal-title":"PLoS ONE"},{"issue":"20","key":"373_CR110","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.Ccr-22-1128","volume":"28","author":"JB Hiatt","year":"2022","unstructured":"Hiatt JB, Sandborg H, Garrison SM, Arnold HU, Liao S-Y, Norton JP, et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. Clin Cancer Res. 2022;28(20):4551\u201364. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1128.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"373_CR111","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2174\/1568026615666150826114359","volume":"16","author":"A Yuqing Yang","year":"2016","unstructured":"Yuqing Yang A, Kim H, Li W, Tony Kong A-N. Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem. 2016;16(7):697\u2013713. https:\/\/doi.org\/10.2174\/1568026615666150826114359.","journal-title":"Curr Top Med Chem"},{"issue":"21","key":"373_CR112","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/anie.200461346","volume":"44","author":"M Biel","year":"2005","unstructured":"Biel M, Wascholowski V, Giannis A. Epigenetics\u2014an epicenter of gene regulation: histones and histone-modifying enzymes. Angew Chem Int Ed Engl. 2005;44(21):3186\u2013216. https:\/\/doi.org\/10.1002\/anie.200461346.","journal-title":"Angew Chem Int Ed Engl"},{"key":"373_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-020-00860-2","volume":"12","author":"S Banday","year":"2020","unstructured":"Banday S, Farooq Z, Ganai SA, Altaf M. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias. Clin Epigenetics. 2020;12:1\u20139. https:\/\/doi.org\/10.1186\/s13148-020-00860-2.","journal-title":"Clin Epigenetics"},{"key":"373_CR114","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2018.00041","volume":"8","author":"Y Sun","year":"2018","unstructured":"Sun Y, Chen B-R, Deshpande A. Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia. Front Oncol. 2018;8:41. https:\/\/doi.org\/10.3389\/fonc.2018.00041.","journal-title":"Front Oncol"},{"issue":"16","key":"373_CR115","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","volume":"23","author":"O Rizq","year":"2017","unstructured":"Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, et al. Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition. Clin Cancer Res. 2017;23(16):4817\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2735.","journal-title":"Clin Cancer Res"},{"issue":"6258","key":"373_CR116","doi-asserted-by":"publisher","first-page":"aac4383","DOI":"10.1126\/science.aac4383","volume":"350","author":"L Jiao","year":"2015","unstructured":"Jiao L, Liu X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science. 2015;350(6258):aac4383. https:\/\/doi.org\/10.1126\/science.aac4383.","journal-title":"Science"},{"issue":"2","key":"373_CR117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41417-022-00555-1","volume":"30","author":"R An","year":"2023","unstructured":"An R, Li Y-Q, Lin Y-L, Xu F, Li M-M, Liu Z. EZH1\/2 as targets for cancer therapy. Cancer Gene Ther. 2023;30(2):221\u201335. https:\/\/doi.org\/10.1038\/s41417-022-00555-1.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"373_CR118","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023;40(6):167. https:\/\/doi.org\/10.1007\/s12032-023-02025-6.","journal-title":"Med Oncol"},{"issue":"7","key":"373_CR119","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.21037\/tau-20-1339","volume":"10","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Hess J, Yamada Y, Ku S-Y, Beltran H. Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021;10(7):3104. https:\/\/doi.org\/10.21037\/tau-20-1339.","journal-title":"Transl Androl Urol"},{"issue":"4","key":"373_CR120","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163","volume":"21","author":"SE Preston","year":"2022","unstructured":"Preston SE, Emond A, Pettersson F, Dup\u00e9r\u00e9-Richer D, Abraham MJ, Riva A, et al. Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines toward an ABC-like phenotype. Mol Cancer Ther. 2022;21(4):511\u201321. https:\/\/doi.org\/10.1158\/1535-7163.","journal-title":"Mol Cancer Ther"},{"key":"373_CR121","doi-asserted-by":"publisher","unstructured":"Verma SK. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer. Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis. 2014:677\u201388. https:\/\/doi.org\/10.1007\/978-1-4939-1804-1_35.","DOI":"10.1007\/978-1-4939-1804-1_35"},{"issue":"4","key":"373_CR122","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385-401.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.008.","journal-title":"Cancer Cell"},{"issue":"1","key":"373_CR123","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.Ccr-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26(1):290\u2013300. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1351.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"373_CR124","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2767-9764.Crc-23-0399","volume":"4","author":"TJ DuCote","year":"2024","unstructured":"DuCote TJ, Song X, Naughton KJ, Chen F, Plaugher DR, Childress AR, et al. Ezh2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas. Cancer Res Commun. 2024;4(2):388\u2013403. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0399.","journal-title":"Cancer Res Commun"},{"issue":"11","key":"373_CR125","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(20)30451-4.","journal-title":"Lancet Oncol"},{"issue":"11","key":"373_CR126","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/s1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30441-1.","journal-title":"Lancet Oncol"},{"key":"373_CR127","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","volume":"37","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, et al. The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review. Adv Ther. 2020;37:3059\u201382. https:\/\/doi.org\/10.1007\/s12325-020-01379-x.","journal-title":"Adv Ther"},{"key":"373_CR128","doi-asserted-by":"publisher","unstructured":"Shin DS, Park K, Garon E, Dubinett S, editors. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Seminars in Oncology; 2022: Elsevier. https:\/\/doi.org\/10.1053\/j.seminoncol.2022.06.005.","DOI":"10.1053\/j.seminoncol.2022.06.005"},{"issue":"2","key":"373_CR129","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40495-015-0018-x","volume":"1","author":"SS Boyanapalli","year":"2015","unstructured":"Boyanapalli SS, Kong A-NT. Curcumin, the king of spices\u201d: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr Pharmacol Rep. 2015;1(2):129\u201339. https:\/\/doi.org\/10.1007\/s40495-015-0018-x.","journal-title":"Curr Pharmacol Rep"},{"key":"373_CR130","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40495-017-0086-1","volume":"3","author":"Z-h Zhou","year":"2017","unstructured":"Zhou Z-h, Yang J, Kong A-N. Phytochemicals in traditional Chinese herbal medicine: cancer prevention and epigenetics mechanisms. Curr Pharmacol Rep. 2017;3:77\u201391. https:\/\/doi.org\/10.1007\/s40495-017-0086-1.","journal-title":"Curr Pharmacol Rep"},{"issue":"10","key":"373_CR131","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.3390\/molecules25102326","volume":"25","author":"O Ciesielski","year":"2020","unstructured":"Ciesielski O, Biesiekierska M, Balcerczyk A. Epigallocatechin-3-gallate (EGCG) alters histone acetylation and methylation and impacts chromatin architecture profile in human endothelial cells. Molecules. 2020;25(10):2326. https:\/\/doi.org\/10.3390\/molecules25102326.","journal-title":"Molecules"},{"issue":"3","key":"373_CR132","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/nu12030761","volume":"12","author":"P Selvakumar","year":"2020","unstructured":"Selvakumar P, Badgeley A, Murphy P, Anwar H, Sharma U, Lawrence K, et al. Flavonoids and other polyphenols act as epigenetic modifiers in breast cancer. Nutrients. 2020;12(3):761. https:\/\/doi.org\/10.3390\/nu12030761.","journal-title":"Nutrients"},{"key":"373_CR133","doi-asserted-by":"publisher","unstructured":"Gerhauser C. Epigenetics, Plant (Poly) phenolics, and Cancer Prevention. Recent advances in polyphenol research. 2014:143\u2013207. https:\/\/doi.org\/10.1002\/9781118329634.ch6.","DOI":"10.1002\/9781118329634.ch6"},{"issue":"3","key":"373_CR134","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pharmthera.2013.12.015","volume":"142","author":"L Sigalotti","year":"2014","unstructured":"Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther. 2014;142(3):339\u201350. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.015.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"373_CR135","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.3390\/ijms20184567","volume":"20","author":"I Arora","year":"2019","unstructured":"Arora I, Sharma M, Tollefsbol TO. Combinatorial epigenetics impact of polyphenols and phytochemicals in cancer prevention and therapy. Int J Mol Sci. 2019;20(18):4567. https:\/\/doi.org\/10.3390\/ijms20184567.","journal-title":"Int J Mol Sci"},{"key":"373_CR136","unstructured":"Bishayee A, Bhatia D. Epigenetics of Cancer prevention. Academic Press; 2018."},{"issue":"6","key":"373_CR137","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood"},{"issue":"1","key":"373_CR138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014.","journal-title":"Cancer Cell"},{"issue":"7274","key":"373_CR139","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344. https:\/\/doi.org\/10.1038\/nature08617.","journal-title":"Nature"},{"issue":"24","key":"373_CR140","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, Botton Sd, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(24):2386\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1716984.","journal-title":"N Engl J Med"},{"issue":"7","key":"373_CR141","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. VorAsidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194.","journal-title":"N Engl J Med"},{"issue":"suppl-16_suppl","key":"373_CR142","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2025.43.16_suppl.2013","volume":"43","author":"JR Ahnert","year":"2025","unstructured":"Ahnert JR, Sepulveda Sanchez JM, Alese OB, Anguera G, Chandrasekharan C, Chawla SP, et al. Phase 1 study of HMPL-306, an inhibitor of mutant IDH1\/IDH2 (mIDH1\/2), in western patients (pts) with advanced mIDH solid tumor, including glioma. J Clin Oncol. 2025;43(suppl-16_suppl):2013. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2013.","journal-title":"J Clin Oncol"},{"issue":"1","key":"373_CR143","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","volume":"6","author":"N Wang","year":"2021","unstructured":"Wang N, Wu R, Tang D, Kang R. The BET family in immunity and disease. Signal Transduct Target Ther. 2021;6(1):23. https:\/\/doi.org\/10.1038\/s41392-020-00384-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"373_CR144","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"SJ Vervoort","year":"2022","unstructured":"Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer. 2022;22(1):5\u201324. https:\/\/doi.org\/10.1038\/s41568-021-00411-8.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"373_CR145","doi-asserted-by":"publisher","first-page":"9719","DOI":"10.1093\/nar\/gkw667","volume":"44","author":"J Shan","year":"2016","unstructured":"Shan J, Zhang F, Sharkey J, Tang TA, \u00d6rd T, Kilberg MS. The C\/ebp-Atf response element (CARE) location reveals two distinct Atf4-dependent, elongation-mediated mechanisms for transcriptional induction of aminoacyl-tRNA synthetase genes in response to amino acid limitation. Nucleic Acids Res. 2016;44(20):9719\u201332. https:\/\/doi.org\/10.1093\/nar\/gkw667.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"373_CR146","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021;124(9):1478\u201390. https:\/\/doi.org\/10.1038\/s41416-021-01321-0.","journal-title":"Br J Cancer"},{"issue":"1","key":"373_CR147","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"Z-Q Wang","year":"2023","unstructured":"Wang Z-Q, Zhang Z-C, Wu Y-Y, Pi Y-N, Lou S-H, Liu T-B, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Signal Transduct Target Ther"},{"key":"373_CR148","doi-asserted-by":"publisher","first-page":"112993","DOI":"10.1016\/j.ejmech.2020.112993","volume":"210","author":"P Mart\u00edn-Acosta","year":"2021","unstructured":"Mart\u00edn-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem. 2021;210:112993. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112993.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"373_CR149","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ddr.22026","volume":"84","author":"HY Zhao","year":"2023","unstructured":"Zhao HY, Xin M, Zhang SQ. Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Dev Res. 2023;84(2):337\u201394. https:\/\/doi.org\/10.1002\/ddr.22026.","journal-title":"Drug Dev Res"},{"issue":"7","key":"373_CR150","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.3390\/molecules28073043","volume":"28","author":"KK To","year":"2023","unstructured":"To KK, Xing E, Larue RC, Li P-K. BET bromodomain inhibitors: novel design strategies and therapeutic applications. Molecules. 2023;28(7):3043. https:\/\/doi.org\/10.3390\/molecules28073043.","journal-title":"Molecules"},{"issue":"5","key":"373_CR151","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728\u201336. https:\/\/doi.org\/10.1016\/j.molcel.2014.05.016.","journal-title":"Mol Cell"},{"key":"373_CR152","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2021","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2021;11:621093. https:\/\/doi.org\/10.3389\/fphar.2020.621093.","journal-title":"Front Pharmacol"},{"issue":"17","key":"373_CR153","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.3390\/cancers14174079","volume":"14","author":"J Hilton","year":"2022","unstructured":"Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, et al. BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial. Cancers (Basel). 2022;14(17):4079. https:\/\/doi.org\/10.3390\/cancers14174079.","journal-title":"Cancers (Basel)"},{"key":"373_CR154","doi-asserted-by":"publisher","unstructured":"Piha-Paul SA, Hann CL, French CA, Cousin S, Bra\u00f1a I, Cassier PA et al. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum. 2020;4(2). https:\/\/doi.org\/10.1093\/jncics\/pkz093.","DOI":"10.1093\/jncics\/pkz093"},{"key":"373_CR155","doi-asserted-by":"publisher","unstructured":"Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M et al. A phase 1b dose-escalation\/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. BLOOD CANCER JOURNAL. 2021;11(9). https:\/\/doi.org\/10.1038\/s41408-021-00545-w.","DOI":"10.1038\/s41408-021-00545-w"},{"issue":"30","key":"373_CR156","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/jco.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin J, Soria J-C, Stathis A, Delord J-P, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36(30):3007\u201314. https:\/\/doi.org\/10.1200\/jco.2018.78.2292.","journal-title":"J Clin Oncol"},{"issue":"9","key":"373_CR157","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2174\/0929867327666200610174453","volume":"28","author":"S Zhang","year":"2021","unstructured":"Zhang S, Chen Y, Tian C, He Y, Tian Z, Wan Y, et al. Dual-target inhibitors based on BRD4: novel therapeutic approaches for cancer. Curr Med Chem. 2021;28(9):1775\u201395. https:\/\/doi.org\/10.2174\/0929867327666200610174453.","journal-title":"Curr Med Chem"},{"issue":"6","key":"373_CR158","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317. https:\/\/doi.org\/10.1016\/j.cell.2011.08.017.","journal-title":"Cell"},{"issue":"7370","key":"373_CR159","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524\u20138. https:\/\/doi.org\/10.1038\/nature10334.","journal-title":"Nature"},{"issue":"7504","key":"373_CR160","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278. https:\/\/doi.org\/10.1038\/nature13229.","journal-title":"Nature"},{"issue":"4","key":"373_CR161","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/nar\/gkad1175","volume":"52","author":"AD Huber","year":"2024","unstructured":"Huber AD, Poudel S, Wu J, Miller DJ, Lin W, Yang L, et al. A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR. Nucleic Acids Res. 2024;52(4):1661\u201376. https:\/\/doi.org\/10.1093\/nar\/gkad1175.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"373_CR162","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejpb.2021.10.017","volume":"171","author":"T Fourniols","year":"2022","unstructured":"Fourniols T, Maggio V, Rafael D, Colaco A, Vidal EG, Lopes A, et al. Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. Eur J Pharm Biopharm. 2022;171(3):39\u201349. https:\/\/doi.org\/10.1016\/j.ejpb.2021.10.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"373_CR163","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2021.01.018","volume":"146","author":"ADJ Pearson","year":"2021","unstructured":"Pearson ADJ, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, et al. Bromodomain and extra-terminal inhibitors\u2014a consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children\u2014ACCELERATE. Eur J Cancer. 2021;146:115\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.018.","journal-title":"Eur J Cancer"},{"issue":"8","key":"373_CR164","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/1568026615666150302110135","volume":"15","author":"L Yu","year":"2015","unstructured":"Yu L, Wang Z, Zhang Z, Ren X, Lu X, Ding K. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential. Curr Top Med Chem. 2015;15(8):776\u201394. https:\/\/doi.org\/10.2174\/1568026615666150302110135.","journal-title":"Curr Top Med Chem"},{"issue":"21","key":"373_CR165","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.Ccr-19-0578","volume":"25","author":"SA Piha-Paul","year":"2019","unstructured":"Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors. Clin Cancer Res. 2019;25(21):6309\u201319. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0578.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"373_CR166","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-cancerbio-070120-103531","volume":"6","author":"P Trojer","year":"2022","unstructured":"Trojer P. Targeting BET bromodomains in cancer. Annual Review of Cancer Biology. 2022;6(1):313\u201336. https:\/\/doi.org\/10.1146\/annurev-cancerbio-070120-103531.","journal-title":"Annual Review of Cancer Biology"},{"issue":"7","key":"373_CR167","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1021\/acs.jmedchem.1c01835","volume":"65","author":"J Chen","year":"2022","unstructured":"Chen J, Tang P, Wang Y, Wang J, Yang C, Li Y, et al. Targeting bromodomain-selective inhibitors of BET proteins in drug discovery and development. J Med Chem. 2022;65(7):5184\u2013211. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01835.","journal-title":"J Med Chem"},{"issue":"7794","key":"373_CR168","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","volume":"578","author":"EJ Faivre","year":"2020","unstructured":"Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578(7794):306\u201310. https:\/\/doi.org\/10.1038\/s41586-020-1930-8.","journal-title":"Nature"},{"issue":"6489","key":"373_CR169","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.aaz8455","volume":"368","author":"O Gilan","year":"2020","unstructured":"Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368(6489):387. https:\/\/doi.org\/10.1126\/science.aaz8455.","journal-title":"Science"},{"key":"373_CR170","doi-asserted-by":"publisher","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","volume":"210","author":"S Zeng","year":"2021","unstructured":"Zeng S, Huang W, Zheng X, Zhang Z, Wang J, Shen Z. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021;210:112981. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112981.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"373_CR171","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer. 2022;21(1):99. https:\/\/doi.org\/10.1186\/s12943-021-01434-3.","journal-title":"Mol Cancer"},{"key":"373_CR172","doi-asserted-by":"publisher","first-page":"102148","DOI":"10.1016\/j.cbpa.2022.102148","volume":"68","author":"MP Schwalm","year":"2022","unstructured":"Schwalm MP, Knapp S. BET bromodomain inhibitors. Curr Opin Chem Biol. 2022;68:102148. https:\/\/doi.org\/10.1016\/j.cbpa.2022.102148.","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"373_CR173","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.7150\/thno.92526","volume":"14","author":"X-J Dai","year":"2024","unstructured":"Dai X-J, Ji S-K, Fu M-J, Liu G-Z, Liu H-M, Wang S-P, et al. Degraders in epigenetic therapy: PROTACs and beyond. Theranostics. 2024;14(4):1464. https:\/\/doi.org\/10.7150\/thno.92526.","journal-title":"Theranostics"},{"key":"373_CR174","doi-asserted-by":"publisher","first-page":"112426","DOI":"10.1016\/j.ejmech.2020.112426","volume":"200","author":"D Liang","year":"2020","unstructured":"Liang D, Yu Y, Ma Z. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. Eur J Med Chem. 2020;200:112426. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112426.","journal-title":"Eur J Med Chem"},{"issue":"15","key":"373_CR175","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2174\/1574885514666190618113519","volume":"20","author":"Y Shi","year":"2019","unstructured":"Shi Y, Liu J, Zhao Y, Cao J, Li Y, Guo F. Bromodomain-containing protein 4: a druggable target. Curr Drug Targets. 2019;20(15):1517\u201336. https:\/\/doi.org\/10.2174\/1574885514666190618113519.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"373_CR176","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","volume":"64","author":"P Tang","year":"2021","unstructured":"Tang P, Zhang J, Liu J, Chiang C-M, Ouyang L. Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development. J Med Chem. 2021;64(5):2419\u201335. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01487.","journal-title":"J Med Chem"},{"key":"373_CR177","doi-asserted-by":"publisher","first-page":"117033","DOI":"10.1016\/j.bmc.2022.117033","volume":"73","author":"X-L Zhou","year":"2022","unstructured":"Zhou X-L, Zhao F, Xu Y-T, Guan Y-Y, Yu T, Zhang Y-Z, et al. A comprehensive review of BET-targeting PROTACs for cancer therapy. Bioorg Med Chem. 2022;73:117033. https:\/\/doi.org\/10.1016\/j.bmc.2022.117033.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"373_CR178","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","volume":"23","author":"M Ramadoss","year":"2018","unstructured":"Ramadoss M, Mahadevan V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today. 2018;23(1):76\u201389. https:\/\/doi.org\/10.1016\/j.drudis.2017.09.011.","journal-title":"Drug Discov Today"},{"issue":"8","key":"373_CR179","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"D Doroshow","year":"2017","unstructured":"Doroshow D, Eder J, LoRusso P. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776\u201387. https:\/\/doi.org\/10.1093\/annonc\/mdx157.","journal-title":"Ann Oncol"},{"issue":"9","key":"373_CR180","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18(9):2162\u201374. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.011.","journal-title":"Cell Rep"},{"issue":"11","key":"373_CR181","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16(11):2829\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.032.","journal-title":"Cell Rep"},{"key":"373_CR182","doi-asserted-by":"publisher","unstructured":"Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T et al. Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021;118(8). https:\/\/doi.org\/10.1073\/pnas.2025840118.","DOI":"10.1073\/pnas.2025840118"},{"issue":"26","key":"373_CR183","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.7150\/thno.30707","volume":"9","author":"J Peng","year":"2019","unstructured":"Peng J, Li J, Huang J, Xu P, Huang H, Liu Y, et al. P300\/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. Theranostics. 2019;9(26):8344\u201361. https:\/\/doi.org\/10.7150\/thno.30707.","journal-title":"Theranostics"},{"issue":"11","key":"373_CR184","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12(11):4935\u201348. https:\/\/doi.org\/10.7150\/thno.73223.","journal-title":"Theranostics"},{"issue":"19","key":"373_CR185","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, et al. P300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene. 2020;39(19):3939\u201351. https:\/\/doi.org\/10.1038\/s41388-020-1270-z.","journal-title":"Oncogene"},{"issue":"7","key":"373_CR186","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","volume":"15","author":"W Farnaby","year":"2019","unstructured":"Farnaby W, Koegl M, Roy MJ, Whitworth C, Diers E, Trainor N, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019;15(7):672\u201380. https:\/\/doi.org\/10.1038\/s41589-019-0294-6.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"373_CR187","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1021\/acs.jmedchem.4c01878","volume":"68","author":"Z Li","year":"2025","unstructured":"Li Z, Harikrishnan LS, Xu G, Samanta D, Clemente JC, Leng L, et al. Discovery of potent, highly selective, and efficacious SMARCA2 degraders. J Med Chem. 2025;68(2):1134\u201354. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01878.","journal-title":"J Med Chem"},{"issue":"1","key":"373_CR188","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KVG Nadiminti","year":"2024","unstructured":"Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113. https:\/\/doi.org\/10.1186\/s13045-024-01632-8.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"373_CR189","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed YY. Revumenib: first approval. Drugs. 2025;85(4):577\u201383. https:\/\/doi.org\/10.1007\/s40265-025-02161-5.","journal-title":"Drugs"},{"issue":"1","key":"373_CR190","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-018-05854-6","volume":"9","author":"J Suzuki","year":"2018","unstructured":"Suzuki J, Yamada T, Inoue K, Nabe S, Kuwahara M, Takemori N, et al. The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation. Nat Commun. 2018;9(1):3296. https:\/\/doi.org\/10.1038\/s41467-018-05854-6.","journal-title":"Nat Commun"},{"key":"373_CR191","doi-asserted-by":"publisher","first-page":"722188","DOI":"10.3389\/fimmu.2021.722188","volume":"12","author":"R Hu","year":"2021","unstructured":"Hu R, Zhou B, Chen Z, Chen S, Chen N, Shen L, et al. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer. Front Immunol. 2021;12:722188. https:\/\/doi.org\/10.3389\/fimmu.2021.722188.","journal-title":"Front Immunol"},{"issue":"1","key":"373_CR192","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13148-023-01482-0","volume":"15","author":"A Sgro","year":"2023","unstructured":"Sgro A, Cursons J, Waryah C, Woodward EA, Foroutan M, Lyu R, et al. Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma. Clin Epigenetics. 2023;15(1):73. https:\/\/doi.org\/10.1186\/s13148-023-01482-0.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"373_CR193","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.1038\/s41467-025-63167-x","volume":"16","author":"D Xu","year":"2025","unstructured":"Xu D, Besselink S, Ramadoss GN, Dierks PH, Lubin JP, Pattali RK, et al. Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins. Nat Commun. 2025;16(1):7948. https:\/\/doi.org\/10.1038\/s41467-025-63167-x.","journal-title":"Nat Commun"},{"issue":"5","key":"373_CR194","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373. https:\/\/doi.org\/10.1016\/j.cell.2015.07.056.","journal-title":"Cell"},{"issue":"5","key":"373_CR195","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974\u201386. https:\/\/doi.org\/10.1016\/j.cell.2015.07.011.","journal-title":"Cell"},{"key":"373_CR196","doi-asserted-by":"publisher","unstructured":"Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M et al. The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2024;16(23). https:\/\/doi.org\/10.3390\/cancers16234058.","DOI":"10.3390\/cancers16234058"},{"issue":"6","key":"373_CR197","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284-300.e21. https:\/\/doi.org\/10.1016\/j.cell.2017.10.022.","journal-title":"Cell"},{"key":"373_CR198","doi-asserted-by":"publisher","unstructured":"Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C. HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers (Basel). 2021;14(1). https:\/\/doi.org\/10.3390\/cancers14010066.","DOI":"10.3390\/cancers14010066"},{"issue":"12","key":"373_CR199","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.Cir-15-0077-t","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, Sodr\u00e9 AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3(12):1375\u201385. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0077-t.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"373_CR200","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","volume":"128","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, et al. Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br J Cancer. 2023;128(12):2227\u201335. https:\/\/doi.org\/10.1038\/s41416-023-02267-1.","journal-title":"Br J Cancer"},{"issue":"1","key":"373_CR201","doi-asserted-by":"publisher","first-page":"7366","DOI":"10.1038\/s41467-024-51500-9","volume":"15","author":"I Pallavicini","year":"2024","unstructured":"Pallavicini I, Frasconi TM, Catozzi C, Ceccacci E, Tiberti S, Haas D, et al. LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8(+) T cell responsiveness. Nat Commun. 2024;15(1):7366. https:\/\/doi.org\/10.1038\/s41467-024-51500-9.","journal-title":"Nat Commun"},{"issue":"1","key":"373_CR202","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/s41467-021-27179-7","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nat Commun. 2021;12(1):6831. https:\/\/doi.org\/10.1038\/s41467-021-27179-7.","journal-title":"Nat Commun"},{"key":"373_CR203","doi-asserted-by":"publisher","unstructured":"Smith AL, Skupa SA, Eiken AP, Reznicek TE, Schmitz E, Williams N et al. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia. JCI Insight. 2024;9(10). https:\/\/doi.org\/10.1172\/jci.insight.177054.","DOI":"10.1172\/jci.insight.177054"},{"issue":"10","key":"373_CR204","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","volume":"40","author":"X Li","year":"2021","unstructured":"Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836\u201350. https:\/\/doi.org\/10.1038\/s41388-020-01636-x.","journal-title":"Oncogene"},{"issue":"14","key":"373_CR205","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment. J Cancer. 2020;11(14):4059\u201372. https:\/\/doi.org\/10.7150\/jca.44622.","journal-title":"J Cancer"},{"issue":"12","key":"373_CR206","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/1535-7163.Mct-11-0525","volume":"10","author":"A Nebbioso","year":"2011","unstructured":"Nebbioso A, Pereira R, Khanwalkar H, Matarese F, Garc\u00eda-Rodr\u00edguez J, Miceli M, et al. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther. 2011;10(12):2394\u2013404. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0525.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"373_CR207","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/2159-8290.Cd-20-1065","volume":"11","author":"V Fresquet","year":"2021","unstructured":"Fresquet V, Garcia-Barchino MJ, Larrayoz M, Celay J, Vicente C, Fernandez-Galilea M, et al. Endogenous retroelement activation by epigenetic therapy reverses the Warburg effect and elicits mitochondrial-mediated cancer cell death. Cancer Discov. 2021;11(5):1268\u201385. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1065.","journal-title":"Cancer Discov"},{"issue":"7954","key":"373_CR208","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134. https:\/\/doi.org\/10.1038\/s41586-023-05812-3.","journal-title":"Nature"},{"issue":"1","key":"373_CR209","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/s2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15\u201326. https:\/\/doi.org\/10.1016\/s2352-3026(23)00338-1.","journal-title":"Lancet Haematol"},{"issue":"23","key":"373_CR210","doi-asserted-by":"publisher","first-page":"2308045","DOI":"10.1002\/advs.202308045","volume":"11","author":"J Huang","year":"2024","unstructured":"Huang J, Yin Q, Wang Y, Zhou X, Guo Y, Tang Y, et al. Ezh2 inhibition enhances PD-L1 protein stability through USP22-mediated deubiquitination in colorectal cancer. Advanced Science. 2024;11(23):2308045. https:\/\/doi.org\/10.1002\/advs.202308045.","journal-title":"Advanced Science"},{"issue":"1","key":"373_CR211","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/s41467-024-48607-4","volume":"15","author":"F Qiu","year":"2024","unstructured":"Qiu F, Jiang P, Zhang G, An J, Ruan K, Lyu X, et al. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat Commun. 2024;15(1):4327. https:\/\/doi.org\/10.1038\/s41467-024-48607-4.","journal-title":"Nat Commun"},{"issue":"7954","key":"373_CR212","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EMM, Wenge DVV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913. https:\/\/doi.org\/10.1038\/s41586-023-05755-9.","journal-title":"Nature"},{"issue":"1","key":"373_CR213","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/s2352-3026(23)00363-0","volume":"11","author":"T de Witte","year":"2024","unstructured":"de Witte T. Oral decitabine plus cedazuridine versus intravenous decitabine. Lancet Haematol. 2024;11(1):e2\u20133. https:\/\/doi.org\/10.1016\/s2352-3026(23)00363-0.","journal-title":"Lancet Haematol"},{"key":"373_CR214","doi-asserted-by":"publisher","unstructured":"Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S. Use of epigenetic drugs in disease: an overview. Genetics & epigenetics. 2014;6:GEG. S12270. https:\/\/doi.org\/10.4137\/GEG.S12270.","DOI":"10.4137\/GEG.S12270"},{"issue":"3","key":"373_CR215","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tcb.2024.08.005","volume":"35","author":"Y Meng","year":"2025","unstructured":"Meng Y, Nerlov C. Epigenetic regulation of hematopoietic stem cell fate. Trends Cell Biol. 2025;35(3):217\u201329. https:\/\/doi.org\/10.1016\/j.tcb.2024.08.005.","journal-title":"Trends Cell Biol"},{"key":"373_CR216","doi-asserted-by":"publisher","first-page":"1273046","DOI":"10.3389\/fmolb.2023.1273046","volume":"10","author":"L Wallace","year":"2023","unstructured":"Wallace L, Obeng EA. Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis. Front Mol Biosci. 2023;10:1273046. https:\/\/doi.org\/10.3389\/fmolb.2023.1273046.","journal-title":"Front Mol Biosci"},{"issue":"8","key":"373_CR217","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","volume":"103","author":"W Li","year":"2024","unstructured":"Li W, Fu Y, Wang W. A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors. Ann Hematol. 2024;103(8):3207\u201317. https:\/\/doi.org\/10.1007\/s00277-024-05691-2.","journal-title":"Ann Hematol"},{"issue":"10","key":"373_CR218","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nbt.1678","volume":"28","author":"TK Kelly","year":"2010","unstructured":"Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28(10):1069\u201378. https:\/\/doi.org\/10.1038\/nbt.1678.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"373_CR219","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.gendis.2018.06.003","volume":"5","author":"M Fardi","year":"2018","unstructured":"Fardi M, Solali S, Hagh MF. Epigenetic mechanisms as a new approach in cancer treatment: an updated review. Genes Dis. 2018;5(4):304\u201311. https:\/\/doi.org\/10.1016\/j.gendis.2018.06.003.","journal-title":"Genes Dis"},{"issue":"3","key":"373_CR220","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jcp.20515","volume":"207","author":"A Roberti","year":"2006","unstructured":"Roberti A, Sala DL, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol. 2006;207(3):571\u201381. https:\/\/doi.org\/10.1002\/jcp.20515.","journal-title":"J Cell Physiol"},{"issue":"3","key":"373_CR221","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JN, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265. https:\/\/doi.org\/10.1002\/mco2.265.","journal-title":"MedComm"},{"issue":"7","key":"373_CR222","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.2022019306","volume":"145","author":"V Shah","year":"2025","unstructured":"Shah V, Giotopoulos G, Osaki H, Meyerhoefer M, Meduri E, Gallego-Crespo A, et al. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation. Blood. 2025;145(7):748\u201364. https:\/\/doi.org\/10.1182\/blood.2022019306.","journal-title":"Blood"},{"key":"373_CR223","doi-asserted-by":"publisher","first-page":"1363364","DOI":"10.3389\/fddsv.2024.1363364","volume":"4","author":"P Rani","year":"2024","unstructured":"Rani P, Mandal P, Rajak BK, Singh DV. A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs. Frontiers in Drug Discovery. 2024;4:1363364. https:\/\/doi.org\/10.3389\/fddsv.2024.1363364.","journal-title":"Frontiers in Drug Discovery"},{"issue":"13","key":"373_CR224","doi-asserted-by":"publisher","first-page":"eadk4423","DOI":"10.1126\/sciadv.adk4423","volume":"10","author":"AA Chomiak","year":"2024","unstructured":"Chomiak AA, Tiedemann RL, Liu Y, Kong X, Cui Y, Wiseman AK, et al. Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling. Sci Adv. 2024;10(13):eadk4423. https:\/\/doi.org\/10.1126\/sciadv.adk4423.","journal-title":"Sci Adv"},{"issue":"1","key":"373_CR225","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13550-025-01268-w","volume":"15","author":"M Naganawa","year":"2025","unstructured":"Naganawa M, Zheng M-Q, Gallezot J-D, Bonomi R, Gu J, Gao H, et al. Assessment of test-retest reproducibility by [18F]Bavarostat for PET imaging of HDAC6. EJNMMI Res. 2025;15(1):76. https:\/\/doi.org\/10.1186\/s13550-025-01268-w.","journal-title":"EJNMMI Res"},{"key":"373_CR226","doi-asserted-by":"publisher","first-page":"116908","DOI":"10.1016\/j.ejmech.2024.116908","volume":"280","author":"X Zhong","year":"2024","unstructured":"Zhong X, Wu X, Zhou Y, Wu R, Yang J, Yin H, et al. PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor. Eur J Med Chem. 2024;280:116908. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116908.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"373_CR227","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/s2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15\u201326. https:\/\/doi.org\/10.1016\/s2352-3026(23)00338-1.","journal-title":"Lancet Haematol"},{"issue":"6","key":"373_CR228","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","volume":"11","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Patel G, Patel C, Brucelle F, Huhn A, Gardberg AS, et al. Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300\/CBP Histone Acetyltransferase Inhibitor. ACS Med Chem Lett. 2020;11(6):1324\u20139. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00155.","journal-title":"ACS Med Chem Lett"},{"key":"373_CR229","doi-asserted-by":"publisher","unstructured":"Crawford MC, Tripu DR, Barritt SA, Jing Y, Gallimore D, Kales SC et al. Comparative analysis of drug-like EP300\/CREBBP acetyltransferase inhibitors. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.05.15.540887.","DOI":"10.1101\/2023.05.15.540887"},{"issue":"26","key":"373_CR230","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AMK, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016;113(26):7124\u20139. https:\/\/doi.org\/10.1073\/pnas.1521738113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"373_CR231","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13(5):514\u201321. https:\/\/doi.org\/10.1038\/nchembio.2329.","journal-title":"Nat Chem Biol"},{"issue":"6241","key":"373_CR232","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376\u201381. https:\/\/doi.org\/10.1126\/science.aab1433.","journal-title":"Science"},{"issue":"1","key":"373_CR233","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","volume":"27","author":"JH Hsu","year":"2020","unstructured":"Hsu JH, Rasmusson T, Robinson J, Pachl F, Read J, Kawatkar S, et al. EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex. Cell Chem Biol. 2020;27(1):41-6.e17. https:\/\/doi.org\/10.1016\/j.chembiol.2019.11.004.","journal-title":"Cell Chem Biol"},{"issue":"2","key":"373_CR234","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","volume":"16","author":"A Ma","year":"2020","unstructured":"Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, et al. Discovery of a first-in-class EZH2 selective degrader. Nat Chem Biol. 2020;16(2):214\u201322. https:\/\/doi.org\/10.1038\/s41589-019-0421-4.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"373_CR235","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13046-020-01728-2","volume":"39","author":"L Ma","year":"2020","unstructured":"Ma L, Bian X, Lin W. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J Exp Clin Cancer Res. 2020;39(1):219. https:\/\/doi.org\/10.1186\/s13046-020-01728-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"373_CR236","doi-asserted-by":"publisher","unstructured":"Li M, Hu Y, Wang J, Xu Y, Hong Y, Zhang L et al. The dual HDAC and PI3K inhibitor, CUDC\u2011907, inhibits tumor growth and stem\u2011like properties by suppressing PTX3 in neuroblastoma. Int J Oncol. 2024;64(2). https:\/\/doi.org\/10.3892\/ijo.2023.5602.","DOI":"10.3892\/ijo.2023.5602"},{"issue":"13","key":"373_CR237","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Decitabine\/cedazuridine: first approval. Drugs. 2020;80(13):1373\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01389-7.","journal-title":"Drugs"},{"issue":"3","key":"373_CR238","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. M6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.004.","journal-title":"Cancer Cell"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00373-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:05:12Z","timestamp":1764752712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00373-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":238,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00373-5","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors are consent to the submission and publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}